# Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer

> **NCT07080216** · PHASE1,PHASE2 · RECRUITING · sponsor: **Suzhou Zelgen Biopharmaceuticals Co.,Ltd** · enrollment: 120 (estimated)

## Conditions studied

- Cervical Cancer

## Interventions

- **BIOLOGICAL:** ZG005
- **DRUG:** Gecacitinib
- **BIOLOGICAL:** Bevacizumab

## Key facts

- **NCT ID:** NCT07080216
- **Lead sponsor:** Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-23
- **Primary completion:** 2027-08
- **Final completion:** 2027-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07080216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07080216, "Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07080216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*